Discussion : Dental implants in patients treated with antiresorptive medication (3)
Although there are only very few cases in the literature with augmentation of bone/sinus lift, these procedures are linked to a functioning vascular recipient site with working osteoclastic resorption and osteoblastic bone formation, and this is compromised in patients with antiresorptive therapy. Due to the denudation of the bone at the recipient site the vascular situation might be even more compromised, possibly resulting in more BP-ONJ cases so that any kind of augmentation should be considered with extreme care.
Dental implants can improve the Qol in patients with antiresorptive therapy (bisphosphonate/denosumab) analogous to patients without antiresorptive therapy. A recently performed systematic review on masticatory performance, bite force, nutritional state and patient’s satisfaction showed that implant-supported dentures were associated with high patient satisfaction regarding denture comfort and bite force. But interestingly these outcomes were not always related with an increase in general QoL. There is no reason, why this should be any different in patients with antiresorptive therapy in the event of implant success. On the other hand the occurrence of BP-ONJ has a huge impact on the QoL of affected patients since the patients report higher negative affection by pain, problems swallowing and social eating even compared to patients with head and neck squamous cell carcinoma. Therefore prevention of BP-ONJ should be one of the primary aims.
The risk of triggering a BP-ONJ by implant therapy in patients with benign diseases seems to be rather small. The risk in patients with malignant diseases is hard to describe since mostly negative examples are published but not the total number of patients receiving implant therapy. The distribution clearly illustrates the necessity for an individual risk assessment as it is recommended by most guidelines and the importance of explaining the possibility of BP-ONJ development to the patient.
The individual risk is influenced by the primary disease and its treatment, such as the antiresorptive medication (substance, duration of application, frequency of application), concomitant therapy, further diseases (e.g. diabetes), further treatments (e.g. head and neck radiation), further factors (e.g. smoking) and existence of former osteonecrosis/present osteonecrosis.
Serial posts:
- Dental implants in patients treated with antiresorptive medication
- Introduction : Dental implants in patients treated with antiresorptive medication
- Results : Dental implants in patients treated with antiresorptive medication (1)
- Results : Dental implants in patients treated with antiresorptive medication (2)
- Discussion : Dental implants in patients treated with antiresorptive medication (2)
- Discussion : Dental implants in patients treated with antiresorptive medication (3)
- Discussion : Dental implants in patients treated with antiresorptive medication (4)
- Reference : Dental implants in patients treated with antiresorptive medication